Trimethoprim/sulfamethoxazole

Trimethoprim/sulfamethoxazole
	Trimethoprim (top) and sulfamethoxazole (bottom)
Combination of
Sulfamethoxazole	Sulfonamide antibiotic
Trimethoprim	Dihydrofolate reductase inhibitor
Clinical data
Trade names	Bactrim, Cotrim, Septra, others
Other names	TMP/SMX, Co-trimoxazole (BAN UK)
AHFS/Drugs.com	Monograph
License data	US DailyMed: Sulfamethoxazole trimethoprim;
Pregnancy; category	AU: C;
Routes of; administration	Oral, Intravenous infusion
ATC code	J01EE01 (WHO) J04AM08 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Identifiers
CAS Number	8064-90-2;
PubChem CID	358641;
ChemSpider	318412;
KEGG	D00285;
ChEBI	CHEBI:3770;
ChEMBL	ChEMBL58061;
CompTox Dashboard (EPA)	DTXSID0032233 ;
	(verify)

Trimethoprim/sulfamethoxazole, sold under the trade names Bactrim, Cotrim (a short form of the British Approved Name, Co-trimoxazole) and Septra, among others, is a fixed-dose combination antibiotic medication used to treat a variety of bacterial infections. It consists of one part trimethoprim to five parts sulfamethoxazole. It is used to treat urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, and cholera, among others. It is used both to treat and prevent pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and other causes of immunosuppression. It can be given orally (swallowed by mouth) or intravenous infusion (slowly injected into a vein with an IV).

Trimethoprim/sulfamethoxazole is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 143rd most commonly prescribed medication in the United States, with more than 3 million prescriptions.